Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. cancer doctors drop pricey drugs with little or no effect

U.S. oncologists, aware that patients are paying more of the costs of expensive cancer drugs, are increasingly declining to prescribe medicines that have scant or no effect, even as a last resort. At least half a dozen drugs, including colon cancer treatments Cyramza, from Eli Lilly & Co, and Stivarga, sold by Bayer AG, aren’t […]

Read More »

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada in Clinical Trials

Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzyme’s Lemtrada® (alemtuzumab) in Clinical Trials – In the extension of two Phase III pivotal studies, 68 and 60 percent of Lemtrada-treated patients received no additional Lemtrada in the prior four years –– Consistent effects seen across relapse, […]

Read More »

Nobel discoveries on DNA repair now fueling cancer drug research

Cancer researchers are just beginning to understand the ramifications of the fundamental discoveries behind the 2015 Nobel Prizes in Chemistry, which were awarded on Wednesday to three scientists for explaining how cells repair mistakes in DNA that occur when cells divide. When deoxyribonucleic acid (DNA) repair mechanisms fail, they predispose people to cancer. That is […]

Read More »

Valeant Fires Back at Critics, Supported by Investor

CHICAGO – In an Oct. 5 filing with the U.S. Securities and Exchange Commission, Valeant Pharmaceuticals International, Inc. (VRX) fired back at critics over its decisions to grow its pipeline through acquisitions and increase the cost of some newly acquired drugs.   In the filing, Valeant said it is not as dependent on the price […]

Read More »

Amgen Fights Fire with Fire in the Biosimilars Market

Thousand Oaks, Calif.-based Amgen (AMGN), faced with generic and biosimilars competition as its blockbusters lose patent protection, is fighting back on a number of fronts.   On Oct. 2, 2015, Novartis (NVS) announced that the U.S. Food and Drug Administration (FDA) had accepted its Biologics License Application (BLA) for its proposed biosimilar to Amgen’s Enbrel […]

Read More »

Express Scripts sees $750 million in spending on new cholesterol drugs

Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers and health plans, said it has reached deals to cover two costly new cholesterol drugs and expects to spend no more than $750 million on them next year. The injected drugs – Repatha from Amgen Inc and Praluent from partners Regeneron […]

Read More »

Arena Stock Jumps as CEO and Co-Founder Resigns at Request of the Board

San Diego-based Arena Pharmaceuticals (ARNA) announced today that its president and chief executive officer, Jack Lief, will retire, as well as stepping down from the company’s board of directors. The announcement says that Lief’s retirement is “at the request of the Board of Directors.” His interim replacement will be Harry Hixson, a current board member. […]

Read More »

Alkermes’ schizophrenia drug Aristada gets FDA nod

The U.S. Food and Drug Administration on Monday approved Alkermes Plc’s longer-acting injectable version of blockbuster schizophrenia pill Abilify, making the treatment available in two doses. Abilify, developed by Japanese drugmaker Otsuka Pharmaceuticals and sold in the United States by Bristol-Myers Squibb Co, is already facing generic competition. Alkermes’ injectable version, Aristada, is expected to […]

Read More »

U.S. Food and Drug Administration Approves New Treatment Combination of Gilead’s Letairis with Tadalafil for Pulmonary Arterial Hypertension (WHO Group 1)

First-Line Combination of Letairis and Tadalafil Reduced Risk of Disease Progression by Nearly 50 Percent Compared to Either Therapy Individually in Study of 605 PAH Patients with WHO Functional Class II-III Symptoms   October 02, 2015 06:19 PM Eastern Daylight Time   FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food […]

Read More »

FDA expands approval of Merck’s Keytruda to lung cancer

The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom